Hyperthermia, chemotherapeutic agents and oncogenic transformation

Hei, Tom K.; Hall, Eric J.; Kushner, Steve; Osmak, R S

doi:10.3109/02656738609016488

Cited by 10 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies, tolerable hyperthermia alone was reported to be insufficient for complete suppression of tumors,27,31 so combination therapy with hyperthermia is necessary for complete tumor suppression. We are continuing our search for suitable drugs to use concomitantly with inductive hyperthermia and ferucarbotran to enhance the antitumor effects.…”

Section: Discussionmentioning

confidence: 99%

Antitumor effects of inductive hyperthermia using magnetic ferucarbotran nanoparticles on human lung cancer xenografts in nude mice

Araya¹,

Kondo²,

Nishikawa³

et al. 2013

OTT

View full text Add to dashboard Cite

BackgroundThe effects of inductive hyperthermia on lung cancer have yet to be fully investigated. Magnetic nanoparticles used in inductive hyperthermia are made-to-order and expensive. This study was performed to investigate the use of ferucarbotran in inductive hyperthermia and to clarify whether inductive hyperthermia using ferucarbotran promotes antitumor effects in vivo using a lung cancer cell line.MethodsWe injected A549 cells subcutaneously into the right thighs of BALB/c nu/nu nude mice. Forty mice with A549 xenografts were then classified into three groups. Group 1 was the control group. All mice in groups 2 and 3 had ferucarbotran injected into their tumors, and mice in group 3 were then subjected to alternating magnetic field irradiation. We evaluated tumor temperature during the hyperthermic procedure, the time course of tumor growth, histologic findings in tumors after hyperthermic treatment, and adverse events.ResultsIntratumor temperature rose rapidly and was maintained at 43°C–45°C for 20 minutes in an alternating magnetic field. Tumor volumes in groups 1 and 2 increased exponentially, but tumor growth in group 3 was significantly suppressed. No severe adverse events were observed. Histologic findings for the tumors in group 3 revealed mainly necrosis.ConclusionInductive hyperthermia using ferucarbotran is a beneficial and promising approach in the treatment of lung cancer. Ferucarbotran is a novel tool for further development of inductive hyperthermia.

show abstract

Section: Discussionmentioning

confidence: 99%

Antitumor effects of inductive hyperthermia using magnetic ferucarbotran nanoparticles on human lung cancer xenografts in nude mice

Araya¹,

Kondo²,

Nishikawa³

et al. 2013

OTT

View full text Add to dashboard Cite

show abstract

“…This combination of treatment was ineffective on the primary tumour, but rapid and massive metastases developed in distant organs including the lung. Furthermore, the chemo-drugs Bleomycin and Cisplatin have been found to turn carcinogenic in vitro by heat-therapy [25] [26] [27].…”

Section: Systemic or Loco-regional Heating?mentioning

confidence: 99%

Heating Preciosity—Trends in Modern Oncological Hyperthermia

Szász¹,

Szász²,

Minnaar³

et al. 2017

OJBIPHY

View full text Add to dashboard Cite

The use of hyperthermia as a treatment in oncology is a common topic for debate. Some researchers expect a breakthrough in oncological treatments with hyperthermia, whereas others have disregarded the method. Serious questions concerning hyperthermia have arisen. Should homogeneous (isothermal) or heterogeneous (selective) heating being used? When we use selective heating (heterogeneity), should the entire tumour be targeted or should the malignant cells be individually selected? Does the mechanism involve thermal cell death or thermally-assisted cell death? Is the goal necrosis or apoptosis? Is hyperthermia safe as a monotherapy or does it have to be combined with conventional treatments? When the selection is local, how do we act on disseminated cells that represent a high risk of life threatening metastases? When local heating is the focus, how should it be carried out with measured and controlled? Our objective is to show how precise, selective heat transfer is necessary to remove malignant cells and, consequently, how hyperthermia as part of the immune-oncology can change the game in this promising field of oncological therapies.

show abstract

“…14 Hyperthermia has been used for many years to treat a wide variety of tumors in both experimental animals and patients. 15,16 The therapeutic effects of hyperthermia are mainly attributed to the heat-induced tumor cytotoxicity, 16,17 alteration of tumor metabolism, 18,19 enhanced blood flow and increased tumor sensitivity to combined chemotherapy or radiotherapy. [20][21][22] It is also reported that hyperthermia can induce cellular damage, necrosis or apoptosis, directly.…”

mentioning

confidence: 99%

“…Intratumoral injection of autologous DC or combination of hyperthermia with other approaches has been demonstrated to be efficient in tumor immunotherapy. 1,[15][16][17] We hypothesize that combination of local hyperthermia (LHT) with intratumoral injection of DC will synergize the benefits of hyperthermia-induced tumor cell apoptosis and HSPs release with DC-mediated tumor antigen uptake and presentation. [27][28][29][30][31][32][33][34][35][36][37] In this study, we evaluated the safety and efficiency of the combined therapy in 9 patients with metastatic melanoma (n 5 9), and compared them with intratumoral injection of immature DC (IT-DC) alone in 9 patients.…”

mentioning

confidence: 99%

Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma

Guo

Zhu

Sheng

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Dendritic cells (DC) are potent antigen-presenting cells that can present tumor antigens chaperoned by heat shock proteins (HSPs), while local hyperthermia (LHT) can increase the expression of HSPs. In this study, we determine if intratumoral injection of immature DC after LHT (LHT1IT-DC) induces systemic antitumor immunity in patients with advanced melanoma, and investigate the potential immunological mechanisms involved in the treatments. Patients were randomly assigned to intratumoral administration of autologous immature DC triweekly, with (LHT1IT-DC, arm A, n 5 9) or without (IT-DC, arm B, n 5 9) LHT. Our results showed that there were no grade 3/4 toxicities. The time to progress (TTP) of arm A was 5 months, significantly longer than that in arm B (2 months, p < 0.05). However, the overall survival time had no statistical difference (13 months vs. 6 months, p > 0.05) between the 2 groups. Our ELISPOT assay showed a significantly increased melanoma-specific IFN-c production in arm A, suggesting that LHT1IT-DC was more effective in the induction of cytotoxic T lymphocytes (CTL) than IT-DC alone. Furthermore, we detected an increased HSPs expression 4 hr after the first LHT, an enhanced Th1/Th2 chemokines production 24 hr after the first LHT1IT-DC treatment, a promoted migration of DC to afferent lymph nodes, and a decreased infiltration of regulatory T cells (CD4 1 CD25 1) and an increased infiltration of active CTL (CD8 1 CD28 1 ) 48 hr after the third DC injection in arm A patients. Therefore, LHT1IT-DC can induce effective specific antitumor immunity and facilitate a Th1-polarized immune response in patients with advanced melanoma. ' 2007 Wiley-Liss, Inc.Key words: dendritic cell; hyperthermia; melanoma; chemokine; heat shock protein; Treg; antitumor immunity Dendritic cells (DC) -based immunotherapy has been shown to be one of the effective and promising strategies to overcome tumor-induced immunosuppression and induce tumor-specific immunity.1 DC are bone marrow-derived antigen presenting cells (APCs) that play a critical role in the induction and regulation of immune responses.2 DC are highly specialized professional APCs with potent capacity to capture and process antigens in the peripheral blood and tissues, and they subsequently migrate to draining lymph nodes where they present antigens to resting lymphocytes. 3 Key elements affect the efficacy of DC-based vaccines in vivo include loading DC with tumor antigens, maturation status of DC, migration of DC to secondary lymphoid organs and the immunization routes.3,4 For immunotherapy, tumor antigens are provided to DC in different forms such as incubating DC with synthetic or native peptides, tumor tissue lysates, purified proteins, tumorderived total RNA or by fusing malignant cells and DC.5-9 However, in certain cases it is difficult to obtain tumor specimen and identify tumor-associated antigens (TAA) or tumor-specific antigens (TSA) in some patients with malignant cancers. Therefore, intratumoral injection of immature DC in situ without loading DC ...

show abstract

Hyperthermia, chemotherapeutic agents and oncogenic transformation

Cited by 10 publications

References 13 publications

Antitumor effects of inductive hyperthermia using magnetic ferucarbotran nanoparticles on human lung cancer xenografts in nude mice

Antitumor effects of inductive hyperthermia using magnetic ferucarbotran nanoparticles on human lung cancer xenografts in nude mice

Heating Preciosity—Trends in Modern Oncological Hyperthermia

Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma

Contact Info

Product

Resources

About